Katrina Altersitz

The rate of alcohol-associated liver disease among women is the rise and physicians must keep it in mind when discussing medical history with their female patients, according to a review presented here. The findings were presented as part of the Postgraduate Course at the ACG Annual Meeting.

When Healio | Cell Therapy Next visited City of Hope in 2019, the institute boasted a robust cell therapy program, having treated 300 patients with the then-newly approved therapy.Today, City of Hope reports more than 1,600 patients have received cell therapy treatment, and the institution has completed or is conducting more than 80 clinical trials across many cancer types, including 35 in solid

In 2018, at the height of the chimeric antigen receptor T-cell therapy revolution and in the heart of its implementation, Healio’s Cell Therapy Next staff went onsite to University of Pennsylvania’s newly minted center. In this tour, experts from Penn walked through the manufacturing, patient involvement and clinical trial boon happening in their daily lives.

VANCOUVER, British Columbia — With alcohol-related disease still on the rise after surging during the COVID-19 pandemic, an expert here discussed treatment options, including liver transplantation, for patients with alcoholic hepatitis. “You have to realize alcoholic liver disease, especially alcoholic hepatitis, is increasing,” Stanley M. Cohen, MD, FACG, professor of medicine

VANCOUVER, British Columbia — Despite recent changes in nomenclature for metabolic dysfunction-associated steatotic liver disease, an expert here noted that clinical pathways largely remain the same and require reinforcing. “Fatty liver has changed its name and this is a result of a global process — a multiyear, multisociety process — that included over 50 countries that

VANCOUVER, British Columbia — The outgoing ACG president delivered his address at the 2023 Annual Scientific Meeting, highlighting the college’s many achievements and ongoing collegiality, as well as his personal gratitude to colleagues. “I enthusiastically report to you that our college is exciting, energetic, effective and financially sound,” Daniel J. Pambianco, MD,

NEW ORLEANS — Cost efficacy of polatuzumab vedotin added to traditional treatments for diffuse large B-cell lymphoma in the front-line requires long-term PFS data, according to a poster presented at ASH Annual Meeting and Exhibition.“After 2 years of follow up, the pola-R-CHP regimen [polatuzumab vedotin (Polivy, Genentech), rituximab (Rituxan; Genentech, Biogen), cyclophosphamide,

NEW ORLEANS — Looking at 185 countries, a projection presented at the ASH Annual Meeting and Exhibition suggests the global burden of non-Hodgkin lymphoma will increase by 778,000 cases by 2040.“We saw the growing incident trends in non-Hodgkin lymphoma particularly among the elderly population and the large increase in the incidence may indicate the growing prevalence of risk factors

NEW ORLEANS — Patients diagnosed with lymphoma were likely to experience anxiety and depression, lowering overall quality of life, according to a presenter at ASH Annual Meeting and Exhibition. “Psychological burden is substantial for people in the first 6 months of their lymphoma or myeloma diagnosis, with the majority experience in anxiety and or depression,” Oreofe O.

WASHINGTON — A leading expert in hepatology called for fellow specialists to embrace a role of education, advocacy and support as part of a proposed national hepatitis C virus elimination program presented during The Liver Meeting.“Our role now is really in support of the primary care practitioner, because we all know that transfer of patient from diagnosis to treatment results in